Cartazolate

Cartazolate
Clinical data
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	In general: uncontrolled;
Identifiers
	IUPAC name Уthyl 4-(butylamino)-1-ethyl-1H-pyrazolo[3,4-b]pyridine-5-carboxylate;
CAS Number	34966-41-1;
PubChem CID	37015;
ChemSpider	33966;
UNII	8K93Z46WPY;
ChEMBL	ChEMBL8184;
CompTox Dashboard (EPA)	DTXSID20188511 ;
Chemical and physical data
Formula	C15H22N4O2
Molar mass	290.367 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(C1=CN=C(N(CC)N=C2)C2=C1NCCCC)OCC;

Cartazolate (SQ-65,396) is a drug of the pyrazolopyridine class. It acts as a GABA_A receptor positive allosteric modulator at the barbiturate binding site of the complex and has anxiolytic effects in animals.^[1]^[2]^[3]^[4] It is also known to act as an adenosine antagonist at the A₁ and A₂ subtypes and as a phosphodiesterase inhibitor.^[5]^[6] Cartazolate was tested in human clinical trials and was found to be efficacious for anxiety but was never marketed.^[7] It was developed by a team at E.R. Squibb and Sons in the 1970s.^[8]

Quick Facts Clinical data, Routes ofadministration ...

See also